Trials / Completed
CompletedNCT01066884
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib [Tarceva] | 150mg po daily |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2010-02-10
- Last updated
- 2016-08-24
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT01066884. Inclusion in this directory is not an endorsement.